Zepp Health (NYSE:ZEPP) Full Year 2024 Results
Key Financial Results
- Revenue: US$182.6m (down 48% from FY 2023).
- Net loss: US$75.7m (loss widened by 144% from FY 2023).
- US$4.68 loss per share (further deteriorated from US$2.04 loss in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Zepp Health Revenues Beat Expectations, EPS Falls Short
Revenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) missed analyst estimates significantly.
Looking ahead, revenue is forecast to grow 13% p.a. on average during the next 2 years, compared to a 7.1% growth forecast for the Electronic industry in the US.
Performance of the American Electronic industry.
The company's shares are up 1.9% from a week ago.
Risk Analysis
Be aware that Zepp Health is showing 2 warning signs in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.